Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 29Uterine Cervical Dysplasia 14Carcinoma, Basal Cell 12Melanoma 10Glioma 6Glioblastoma 6Breast Neoplasms 5Uterine Cervical Neoplasms 4Neoplasm Metastasis 4Keratosis 4Condylomata Acuminata 4Precancerous Conditions 3Papillomavirus Infections 3Hutchinson's Melanotic Freckle 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Squamous Intraepithelial Lesions 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasms 2Hemangioma, Capillary 2HIV Infections 2Ependymoma 2Colorectal Neoplasms 2Brain Neoplasms 2Astrocytoma 2Warts 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Vaginal Neoplasms 1Stomach Neoplasms 1

Interventions

Specimen Handling 2Nivolumab 2toripalimab 1talimogene laherparepvec 1pembrolizumab 1bicalutamide 1Magnetic Resonance Spectroscopy 1Lidocaine 1Ipilimumab 1Imiquimod 1Fluorescein 1CTLA-4 Antigen 1Biopsy 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paget Disease, Extramammary × Imiquimod × Clear all
NCT02385188 2020-01-02

Topical 5% Imiquimod Cream for Vulvar Paget's Disease

University Medical Center Nijmegen

Phase 3 Completed
25 enrolled

Paget Disease, Extramammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡